Furthermore, examining SF3A2's pan-cancer prognostic implications through Kaplan-Meier survival assessment revealed that increased SF3A2 corresponded to diminished OS in ACC, KIRP, LIHC, LUAD, MESO, PCPG, SARC patients (Figure 3G-M). Here, SF3A2 is linked to cancer.